Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Mar;23(3):313-9.
doi: 10.1038/gt.2015.109. Epub 2015 Dec 24.

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure

B Greenberg  1 , J Butler  2 , G M Felker  3 , P Ponikowski  4 , A A Voors  5 , J M Pogoda  6 , R Provost  6 , J Guerrero  6 , R J Hajjar  7 , K M Zsebo  8
Affiliations
Clinical Trial

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure

B Greenberg et al. Gene Ther. 2016 Mar.

Abstract

Adeno-associated virus serotype 1 (AAV1) has many advantages as a gene therapy vector, but the presence of pre-existing neutralizing antibodies (NAbs) is an important limitation. This study was designed to determine: (1) characteristics of AAV NAbs in human subjects, (2) prevalence of AAV1 NAbs in heart failure patients and (3) utility of aggressive immunosuppressive therapy in reducing NAb seroconversion in an animal model. NAb titers were assessed in a cohort of heart failure patients and in patients screened for a clinical trial of gene therapy with AAV1 carrying the sarcoplasmic reticulum calcium ATPase gene (AAV1/SERCA2a). AAV1 NAbs were found in 59.5% of 1552 heart failure patients. NAb prevalence increased with age (P=0.001) and varied geographically. The pattern of NAb titers suggested that exposure is against AAV2, with AAV1 NAb seropositivity due to crossreactivity. The effects of immunosuppression on NAb formation were tested in mini-pigs treated with immunosuppressant therapy before, during and after a single AAV1/SERCA2a infusion. Aggressive immunosuppression did not prevent formation of AAV1 NAbs. We conclude that immunosuppression is unlikely to be a viable solution for repeat AAV1 dosing. Strategies to reduce NAbs in heart failure patients are needed to increase eligibility for gene transfer using AAV vectors.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

This study was funded by Celladon Corporation (San Diego, CA, USA). Drs Greenberg, Butler, Felker, Ponikowski, Voors and Hajjar have received compensation for consultancies or board memberships from Celladon Corporation, the sponsor of this study. Drs Pogoda, Provost, Guerrero and Zsebo are former employees of Celladon.

Figures

Figure 1.
Figure 1.
Prevalence of AAV1 NAbs in (a) Europe and Israel (N = 618) and (b) the United States (N = 934) as determined by titers ⩾ 1:2. One state (North Carolina) was not included because of small sample size (n = 3). AAV1, adeno-associated virus 1; NAbs, neutralizing antibodies.
Figure 2.
Figure 2.
Prevalence of AAV1 NAbs by (a) gender and (b) age as determined by titers ⩾ 1:2 (N = 1552).
See this image and copyright information in PMC

References

    1. Pleger SV, Brinks H, Ritterhoff J, Raake P, Koch WJ, Katus HA et al. Heart failure gene therapy: the path to clinical practice. Circ Res 2013; 113: 792–809. - PMC - PubMed
    1. Du L, Kido M, Lee DV, Rabinowitz JE, Samulski RJ, Jamieson SW et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004; 10: 604–608. - PubMed
    1. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171–181. - PMC - PubMed
    1. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac diseases (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum CA2 +-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304–313. - PMC - PubMed
    1. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure. Analysis of recurrent cardiovascular events and mortality. Circ Res 2014; 114: 101–108. - PubMed

Publication types

Substances